Related Experiment Video
Updated: Mar 23, 2026

A Cell Culture Model for Producing High Titer Hepatitis E Virus Stocks
Published on: June 26, 2020
Abacavir-induced liver toxicity.
Maria Diletta Pezzani1, Chiara Resnati1, Valentina Di Cristo1
1Università di Milano, Luigi Sacco University Hospital, Department of Biomedical and Clinical Sciences L. Sacco, Milan, Italy.
Abacavir liver toxicity is rare in HLA B*5701-negative individuals. This study details a case in a patient negative for the HLA B*5701 allele who developed liver issues after switching to abacavir.
Area of Science:
- Pharmacogenomics
- Hepatology
- Infectious Disease
Background:
- Abacavir is an effective antiretroviral medication.
- Abacavir-induced liver toxicity is typically associated with the HLA B*5701 allele.
- Identifying risk factors for drug-induced liver injury is crucial for patient safety.
Observation:
- A case of abnormal liver function tests is presented in a young, HLA B*5701-negative woman.
- The patient was on a stable nevirapine-based regimen and had no prior liver issues or alcohol abuse.
- Abnormal liver function occurred after switching from tenofovir to abacavir.
Findings:
- This case suggests abacavir may cause liver toxicity even in HLA B*5701-negative patients.
- Further investigation into abacavir discontinuation reasons in a patient cohort treated with abacavir-lamivudine-nevirapine was conducted.
Implications:
- The findings highlight the need for vigilance regarding abacavir hepatotoxicity, irrespective of HLA B*5701 status.
- This case may prompt re-evaluation of screening protocols for abacavir-related liver injury.
- Understanding diverse mechanisms of drug-induced liver injury is essential for optimizing HIV treatment regimens.
More Related Videos
11:34A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
Published on: May 10, 2022
11:36Induction of Drug-Induced, Autoimmune Hepatitis in BALB/c Mice for the Study of Its Pathogenic Mechanisms
Published on: May 29, 2020
Related Concept Videos
Hepatitis
Effect of Hepatic Disease on Pharmacokinetics: Dose Adjustments Due to Hepatic Impairment
Hepatic Drug Excretion: Influencing Factors
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
Inhibitors of Viral Protein Synthesis
Drug Toxicity: Risk factors